Effects of mesenchymal stem cells therapy in peritoneal dialysis patients
Not Applicable
- Conditions
- Chronic kidney disease.Chronic kidney disease, stage 5
- Registration Number
- IRCT2015052415841N2
- Lead Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients on peritoneal dialysis; Both sexes; Age between 18-70 years; Being on peritoneal dialysis for at least last two years; Having Ultrafiltration failure
Exclusion criteria: Patients who cannot come for regular visits; Patients with less than 1 year survival; Patients on immunosuppressive medications; Pregnancy; Malignancy; Coagulative disorders
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method D/P cr. Timepoint: Before and at week 3, week 6, month 3, month 4 and month 6. Method of measurement: Ratio of 4-hour dialysate/plasma creatinine.;D/P urea. Timepoint: Before and at week 3, week 6, month 3, month 4 and month 6. Method of measurement: Ratio of 4-hour dialysate/plasma urea.;D0/D glucose. Timepoint: Before and at week 3, week 6, month 3, month 4 and month 6. Method of measurement: Ratio of dialysate glucose concentrations at end and at start of tests.;Peritoneal Equilibration Test (PET). Timepoint: Before and at week 3, week 6, month 3, month 4 and month 6. Method of measurement: Assessment of peritoneal membrane transport function by machine.
- Secondary Outcome Measures
Name Time Method Glomerular filtration rate (GFR). Timepoint: Before and at week 3, week 6, month 3, month 4 and month 6. Method of measurement: MDRD formula.;Kt/V urea. Timepoint: Before and at week 3, week 6, month 3, month 4 and month 6. Method of measurement: Dialyzer clearance of urea * dialysis time/ volume of distribution of urea.